[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse GSN

Summary
SymbolGSN
Namegelsolin
Aliases DKFZp313L0718; amyloidosis, Finnish type; gelsolin (amyloidosis, Finnish type); AGEL; brevin
Chromosomal Location9q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 2: Cytoplasm, cytoskeleton.; SUBCELLULAR LOCATION: Isoform 1: Secreted.
Domain PF00626 Gelsolin repeat
Function

Calcium-regulated, actin-modulating protein that binds to the plus (or barbed) ends of actin monomers or filaments, preventing monomer exchange (end-blocking or capping). It can promote the assembly of monomers into filaments (nucleation) as well as sever filaments already formed. Plays a role in ciliogenesis.

> Gene Ontology
 
Biological Process GO:0001766 membrane raft polarization
GO:0001767 establishment of lymphocyte polarity
GO:0001768 establishment of T cell polarity
GO:0002011 morphogenesis of an epithelial sheet
GO:0002694 regulation of leukocyte activation
GO:0003012 muscle system process
GO:0003014 renal system process
GO:0006909 phagocytosis
GO:0006911 phagocytosis, engulfment
GO:0007015 actin filament organization
GO:0007159 leukocyte cell-cell adhesion
GO:0007163 establishment or maintenance of cell polarity
GO:0008064 regulation of actin polymerization or depolymerization
GO:0008154 actin polymerization or depolymerization
GO:0010324 membrane invagination
GO:0010639 negative regulation of organelle organization
GO:0010950 positive regulation of endopeptidase activity
GO:0010952 positive regulation of peptidase activity
GO:0010954 positive regulation of protein processing
GO:0014888 striated muscle adaptation
GO:0014889 muscle atrophy
GO:0014891 striated muscle atrophy
GO:0016485 protein processing
GO:0019058 viral life cycle
GO:0022407 regulation of cell-cell adhesion
GO:0030010 establishment of cell polarity
GO:0030041 actin filament polymerization
GO:0030042 actin filament depolymerization
GO:0030198 extracellular matrix organization
GO:0030260 entry into host cell
GO:0030832 regulation of actin filament length
GO:0030833 regulation of actin filament polymerization
GO:0030834 regulation of actin filament depolymerization
GO:0030835 negative regulation of actin filament depolymerization
GO:0030837 negative regulation of actin filament polymerization
GO:0030838 positive regulation of actin filament polymerization
GO:0031333 negative regulation of protein complex assembly
GO:0031334 positive regulation of protein complex assembly
GO:0031532 actin cytoskeleton reorganization
GO:0031579 membrane raft organization
GO:0031580 membrane raft distribution
GO:0031647 regulation of protein stability
GO:0031648 protein destabilization
GO:0032271 regulation of protein polymerization
GO:0032272 negative regulation of protein polymerization
GO:0032273 positive regulation of protein polymerization
GO:0032507 maintenance of protein location in cell
GO:0032535 regulation of cellular component size
GO:0032878 regulation of establishment or maintenance of cell polarity
GO:0032956 regulation of actin cytoskeleton organization
GO:0032970 regulation of actin filament-based process
GO:0032984 macromolecular complex disassembly
GO:0035313 wound healing, spreading of epidermal cells
GO:0042110 T cell activation
GO:0042989 sequestering of actin monomers
GO:0043062 extracellular structure organization
GO:0043113 receptor clustering
GO:0043241 protein complex disassembly
GO:0043242 negative regulation of protein complex disassembly
GO:0043244 regulation of protein complex disassembly
GO:0043254 regulation of protein complex assembly
GO:0043280 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043500 muscle adaptation
GO:0043624 cellular protein complex disassembly
GO:0043900 regulation of multi-organism process
GO:0043901 negative regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0044089 positive regulation of cellular component biogenesis
GO:0044319 wound healing, spreading of cells
GO:0044409 entry into host
GO:0044855 plasma membrane raft distribution
GO:0044856 plasma membrane raft localization
GO:0044858 plasma membrane raft polarization
GO:0045010 actin nucleation
GO:0045185 maintenance of protein location
GO:0045862 positive regulation of proteolysis
GO:0046596 regulation of viral entry into host cell
GO:0046597 negative regulation of viral entry into host cell
GO:0046718 viral entry into host cell
GO:0048525 negative regulation of viral process
GO:0050792 regulation of viral process
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0051014 actin filament severing
GO:0051016 barbed-end actin filament capping
GO:0051125 regulation of actin nucleation
GO:0051127 positive regulation of actin nucleation
GO:0051235 maintenance of location
GO:0051249 regulation of lymphocyte activation
GO:0051258 protein polymerization
GO:0051261 protein depolymerization
GO:0051493 regulation of cytoskeleton organization
GO:0051494 negative regulation of cytoskeleton organization
GO:0051495 positive regulation of cytoskeleton organization
GO:0051604 protein maturation
GO:0051651 maintenance of location in cell
GO:0051665 membrane raft localization
GO:0051668 localization within membrane
GO:0051693 actin filament capping
GO:0051701 interaction with host
GO:0051806 entry into cell of other organism involved in symbiotic interaction
GO:0051828 entry into other organism involved in symbiotic interaction
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0060271 cilium morphogenesis
GO:0061041 regulation of wound healing
GO:0070293 renal absorption
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070613 regulation of protein processing
GO:0071593 lymphocyte aggregation
GO:0071800 podosome assembly
GO:0071801 regulation of podosome assembly
GO:0072657 protein localization to membrane
GO:0090066 regulation of anatomical structure size
GO:0090504 epiboly
GO:0090505 epiboly involved in wound healing
GO:0090527 actin filament reorganization
GO:0097017 renal protein absorption
GO:0097283 keratinocyte apoptotic process
GO:0097284 hepatocyte apoptotic process
GO:0097435 fibril organization
GO:0099024 plasma membrane invagination
GO:1900756 protein processing in phagocytic vesicle
GO:1901879 regulation of protein depolymerization
GO:1901880 negative regulation of protein depolymerization
GO:1902115 regulation of organelle assembly
GO:1902172 regulation of keratinocyte apoptotic process
GO:1902174 positive regulation of keratinocyte apoptotic process
GO:1903034 regulation of response to wounding
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903317 regulation of protein maturation
GO:1903319 positive regulation of protein maturation
GO:1903689 regulation of wound healing, spreading of epidermal cells
GO:1903900 regulation of viral life cycle
GO:1903901 negative regulation of viral life cycle
GO:1903903 regulation of establishment of T cell polarity
GO:1903906 regulation of plasma membrane raft polarization
GO:1903909 regulation of receptor clustering
GO:1903921 regulation of protein processing in phagocytic vesicle
GO:1903923 positive regulation of protein processing in phagocytic vesicle
GO:1904019 epithelial cell apoptotic process
GO:1904035 regulation of epithelial cell apoptotic process
GO:1904037 positive regulation of epithelial cell apoptotic process
GO:1905330 regulation of morphogenesis of an epithelium
GO:1990000 amyloid fibril formation
GO:2000114 regulation of establishment of cell polarity
GO:2000116 regulation of cysteine-type endopeptidase activity
GO:2001056 positive regulation of cysteine-type endopeptidase activity
GO:2001233 regulation of apoptotic signaling pathway
GO:2001235 positive regulation of apoptotic signaling pathway
GO:2001267 regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway
GO:2001269 positive regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway
Molecular Function GO:0003779 actin binding
GO:0017022 myosin binding
GO:0045159 myosin II binding
Cellular Component GO:0002102 podosome
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0005938 cell cortex
GO:0015629 actin cytoskeleton
GO:0016528 sarcoplasm
GO:0030055 cell-substrate junction
GO:0030478 actin cap
GO:0030863 cortical cytoskeleton
GO:0030864 cortical actin cytoskeleton
GO:0044448 cell cortex part
GO:0072562 blood microparticle
GO:0099568 cytoplasmic region
> KEGG and Reactome Pathway
 
KEGG hsa04666 Fc gamma R-mediated phagocytosis
hsa04810 Regulation of actin cytoskeleton
Reactome R-HSA-977225: Amyloid fiber formation
R-HSA-109581: Apoptosis
R-HSA-111465: Apoptotic cleavage of cellular proteins
R-HSA-75153: Apoptotic execution phase
R-HSA-264870: Caspase-mediated cleavage of cytoskeletal proteins
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-392499: Metabolism of proteins
R-HSA-6798695: Neutrophil degranulation
R-HSA-5357801: Programmed Cell Death
Summary
SymbolGSN
Namegelsolin
Aliases DKFZp313L0718; amyloidosis, Finnish type; gelsolin (amyloidosis, Finnish type); AGEL; brevin
Chromosomal Location9q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between GSN and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between GSN and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
27685836Lung CarcinomaPromote immunity (T cell function); essential for immunotherapyIt is therefore essential to engineer therapeutic interventions by which T cell reactivity against tumor cells is selectively enhanced (i.e., "focused cancer immunotherapy") based on tumor antigens that are specifically expressed in the tumor of a certain cancer and in many patients with this cancer. This analysis indicated that gelsolin and inter-alpha-trypsin inhibitor heavy chains were specifically and frequently detected (at a frequency higher than 80%), and that phosphoproteins (VENTX, VCIP135) were also specifically present in the ICs of lung cancer patients.
Summary
SymbolGSN
Namegelsolin
Aliases DKFZp313L0718; amyloidosis, Finnish type; gelsolin (amyloidosis, Finnish type); AGEL; brevin
Chromosomal Location9q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of GSN in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolGSN
Namegelsolin
Aliases DKFZp313L0718; amyloidosis, Finnish type; gelsolin (amyloidosis, Finnish type); AGEL; brevin
Chromosomal Location9q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of GSN in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.6310.0316
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.5530.876
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.6860.789
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1680.758
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3110.921
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0110.998
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4320.424
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.7220.757
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1790.943
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.9280.706
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.8730.602
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1480.158
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of GSN in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.407.40.0709
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.407.40.096
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolGSN
Namegelsolin
Aliases DKFZp313L0718; amyloidosis, Finnish type; gelsolin (amyloidosis, Finnish type); AGEL; brevin
Chromosomal Location9q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GSN. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolGSN
Namegelsolin
Aliases DKFZp313L0718; amyloidosis, Finnish type; gelsolin (amyloidosis, Finnish type); AGEL; brevin
Chromosomal Location9q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GSN. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GSN.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolGSN
Namegelsolin
Aliases DKFZp313L0718; amyloidosis, Finnish type; gelsolin (amyloidosis, Finnish type); AGEL; brevin
Chromosomal Location9q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GSN. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolGSN
Namegelsolin
Aliases DKFZp313L0718; amyloidosis, Finnish type; gelsolin (amyloidosis, Finnish type); AGEL; brevin
Chromosomal Location9q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of GSN expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolGSN
Namegelsolin
Aliases DKFZp313L0718; amyloidosis, Finnish type; gelsolin (amyloidosis, Finnish type); AGEL; brevin
Chromosomal Location9q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between GSN and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolGSN
Namegelsolin
Aliases DKFZp313L0718; amyloidosis, Finnish type; gelsolin (amyloidosis, Finnish type); AGEL; brevin
Chromosomal Location9q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting GSN collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting GSN.
ID Name Drug Type Targets #Targets
DB01593ZincSmall MoleculeA1BG, A2M, AGT, AHSG, ALDOA, APCS, APLP1, APLP2, APOA1, APOA2, APO ......119
DB02621Latrunculin ASmall MoleculeACTA1, GSN2
DB09130CopperSmall MoleculeA1BG, ACTG1, ACTN1, ACY1, AFM, AGT, AHCY, AHSG, AKR1A1, ANXA4, ANX ......141